CELSCISci Corp (CVM, Financial) filed Quarterly Report for the period ended 2010-06-30.
Celscisci Corp has a market cap of $102.33 million; its shares were traded at around $0.5 with and P/S ratio of 1263.35. Celscisci Corp had an annual average earning growth of 10.1% over the past 5 years.
cash used in operating activities totaled $9,064,665 and $3,044,463,
respectively. For the nine months ended June 30, 2010 and 2009, cash provided by
financing activities totaled $6,308,874 and $6,985,892, respectively. The
repayment of the Series K convertible notes ($630,000), financing costs
($339,330) and the repayment of the short-term loan ($200,000) was used in
financing activities during the nine months ended June 30, 2009. Licensing
proceeds of $1,249,981 and receipt of short-term loans to the Company of
$1,060,000 provided funds, as did the June 2009 financing ($5,845,241). For the
nine months ended June 30, 2010, cash provided by financing was from the
exercise of warrants and options ($6,308,874). Cash used by investing activities
was $336,089 and provided by investing activities was $918,724, respectively,
for the nine months ended June 30, 2010 and 2009. The use of cash in investing
activities consisted of purchases of equipment and legal costs incurred in
patent applications and, for the nine months ended June 30, 2009, the sale of
the final $200,000 in ARPs.
During the nine-month period ended June 30, 2010, research and development
expenses increased by $3,900,962 compared to the nine-month period ended June
30, 2009. This increase was due to continuing expenses relating to the
preparation for the Phase III clinical trial. During the three month period
ended June 30, 2010, research and development expenses increased by $413,454
compared to the three-month period ended June 30, 2009 for the same reason.
During the nine-month period ended June 30, 2010, general and administrative
expenses increased by $931,843 compared to the nine-month period ended June 30,
2009. During the three-month period ended June 30, 2010, general and
administrative expenses decreased by $243,531 compared to the three-month period
ended June 30, 2009. This increase for the nine months ended June 30, 2010 was
caused by higher costs for employee options and a bonus given to the Company's
Chief Executive Officer in the three-months ended March 31, 2010. The decrease
in the three month period ended June 30, 2010 was due to a reduced cost of
employee options when compared to the three month period ended June 30, 2009.
The interest expense of $120,924 for the nine months ended June 30, 2010 was
interest on the loan from the Company's president, offset by the amortization of
the remaining premium on the loan of ($3,282). The interest expense of $41,402
for the three months ended June 30, 2010 also represented interest on the loan
from the Company's president. The interest expense of $614,654 for the nine
months ended June 30, 2009 was composed of five elements: 1) amortization of the
Series K discount ($111,990), 2) interest paid and accrued on the Series K debt
($103,784), 3) margin interest ($813), 4) interest on the short term loan
($39,265), and 5) cost of warrants issued to short term loan holder ($358,802).
The interest expense of $445,161 for the three months ended June 30, 2009 was
composed of four elements: 1) amortization of the Series K discount ($31,439),
2) interest paid and accrued on the Series K debt ($29,134), 3) interest on the
short term loan ($25,786), and 4) cost of warrants issued to short term loan
holder ($358,802).
MULTIKINE $6,823,218 $3,769,302 $1,434,208 $1,165,834
L.E.A.P.S 910,326 63,280 153,312 8,232
- - - -
TOTAL $7,733,544 $3,832,582 $1,587,520 $1,174,066
= = = =
Read the The complete Report
Celscisci Corp has a market cap of $102.33 million; its shares were traded at around $0.5 with and P/S ratio of 1263.35. Celscisci Corp had an annual average earning growth of 10.1% over the past 5 years.
Highlight of Business Operations:
, 2009. For the nine months ended June 30, 2010 and 2009,cash used in operating activities totaled $9,064,665 and $3,044,463,
respectively. For the nine months ended June 30, 2010 and 2009, cash provided by
financing activities totaled $6,308,874 and $6,985,892, respectively. The
repayment of the Series K convertible notes ($630,000), financing costs
($339,330) and the repayment of the short-term loan ($200,000) was used in
financing activities during the nine months ended June 30, 2009. Licensing
proceeds of $1,249,981 and receipt of short-term loans to the Company of
$1,060,000 provided funds, as did the June 2009 financing ($5,845,241). For the
nine months ended June 30, 2010, cash provided by financing was from the
exercise of warrants and options ($6,308,874). Cash used by investing activities
was $336,089 and provided by investing activities was $918,724, respectively,
for the nine months ended June 30, 2010 and 2009. The use of cash in investing
activities consisted of purchases of equipment and legal costs incurred in
patent applications and, for the nine months ended June 30, 2009, the sale of
the final $200,000 in ARPs.
During the nine-month period ended June 30, 2010, research and development
expenses increased by $3,900,962 compared to the nine-month period ended June
30, 2009. This increase was due to continuing expenses relating to the
preparation for the Phase III clinical trial. During the three month period
ended June 30, 2010, research and development expenses increased by $413,454
compared to the three-month period ended June 30, 2009 for the same reason.
During the nine-month period ended June 30, 2010, general and administrative
expenses increased by $931,843 compared to the nine-month period ended June 30,
2009. During the three-month period ended June 30, 2010, general and
administrative expenses decreased by $243,531 compared to the three-month period
ended June 30, 2009. This increase for the nine months ended June 30, 2010 was
caused by higher costs for employee options and a bonus given to the Company's
Chief Executive Officer in the three-months ended March 31, 2010. The decrease
in the three month period ended June 30, 2010 was due to a reduced cost of
employee options when compared to the three month period ended June 30, 2009.
The interest expense of $120,924 for the nine months ended June 30, 2010 was
interest on the loan from the Company's president, offset by the amortization of
the remaining premium on the loan of ($3,282). The interest expense of $41,402
for the three months ended June 30, 2010 also represented interest on the loan
from the Company's president. The interest expense of $614,654 for the nine
months ended June 30, 2009 was composed of five elements: 1) amortization of the
Series K discount ($111,990), 2) interest paid and accrued on the Series K debt
($103,784), 3) margin interest ($813), 4) interest on the short term loan
($39,265), and 5) cost of warrants issued to short term loan holder ($358,802).
The interest expense of $445,161 for the three months ended June 30, 2009 was
composed of four elements: 1) amortization of the Series K discount ($31,439),
2) interest paid and accrued on the Series K debt ($29,134), 3) interest on the
short term loan ($25,786), and 4) cost of warrants issued to short term loan
holder ($358,802).
MULTIKINE $6,823,218 $3,769,302 $1,434,208 $1,165,834
L.E.A.P.S 910,326 63,280 153,312 8,232
- - - -
TOTAL $7,733,544 $3,832,582 $1,587,520 $1,174,066
= = = =
Read the The complete Report
